# Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

*PRI Rank #16 · Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026/rank-16*

| Field | Value |
| --- | --- |
| Rank | #16 |
| 18m citations | 44 |
| Journal | Journal of Clinical Oncology |
| Year | 2024 |
| DOI | 10.1200/jco.23.02329 |
| Corresponding authors | Lihua E Budde |
| Institution | City of Hope National Medical Center, United States |

**Ranking page:** [Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026](https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026)

**Paper link:** [10.1200/jco.23.02329](https://doi.org/10.1200/jco.23.02329)

## Topics

Mosunetuzumab · CD20-targeted therapy · T-cell-engaging bispecific antibody · relapsed/refractory indolent B-cell non-Hodgkin lymphoma · relapsed/refractory aggressive B-cell non-Hodgkin lymphoma · Fixed-duration treatment · Off-the-shelf therapy · Outpatient administration · Phase I/II trial · Duration of response · Complete response rate · retreatment upon progression · durable remission · NCT02500407 · extended follow-up analysis · Objective response rate

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026. Accessed 2026-07-15.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```